Shanghai Henlius Biotech, Inc.
2696
Rangering i aksjer
#4250
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Aksjekurs
$6.84
Markedsverdi
$3.73B
Endring (1 dag)
2.29%
Endring (1 år)
-27.54%
Land
CN
Handel Shanghai Henlius Biotech, Inc. (2696)
Kategori
Healthcare
P/B-forhold for Shanghai Henlius Biotech, Inc. (2696)
P/B-forhold per October 2026 TTM: 5.10
Ifølge Shanghai Henlius Biotech, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 5.10. Ved slutten av 2023 hadde selskapet et P/B-forhold på 3.30.
P/B-historikk for Shanghai Henlius Biotech, Inc. fra 2017 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 5.10 | 27.22% |
| 2024 | 4.01 | 21.50% |
| 2023 | 3.30 | -11.75% |
| 2022 | 3.74 | -10.95% |
| 2021 | 4.20 | -35.23% |
| 2020 | 6.49 | 43.48% |
| 2019 | 4.52 | -63.92% |
| 2018 | 12.54 | -104.52% |
| 2017 | -277.11 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | 22.53% |
US
|
|
| 13.2547 | 159.81% |
US
|
|
| 4.208 | -17.52% |
AU
|
|
| 6.1824 | 21.18% |
NL
|
|
| - | - |
CH
|
